نتایج جستجو برای: nras

تعداد نتایج: 2055  

Journal: :Blood 2016
Marc S Raab Nicola Lehners Jing Xu Anthony D Ho Peter Schirmacher Hartmut Goldschmidt Mindaugas Andrulis

Recent reports on the genetic landscape of the plasma cell malignancy, multiple myeloma (MM), have revealed potential therapeutic targets such as activating mutations in BRAF kinase in subsets of patients. However, assuming suitable targeted therapies become available, clonal evolution and widespread intraclonal heterogeneity in MMwill pose a challenge to their routine clinical use. Wewere thef...

Journal: :Molecular cancer therapeutics 2014
Junfeng Xia Peilin Jia Katherine E Hutchinson Kimberly B Dahlman Douglas Johnson Jeffrey Sosman William Pao Zhongming Zhao

Next generation sequencing (NGS) has been used to characterize the overall genomic landscape of melanomas. Here, we systematically examined mutations from recently published melanoma NGS data involving 241 paired tumor-normal samples to identify potentially clinically relevant mutations. Melanomas were characterized according to an in-house clinical assay that identifies well-known specific rec...

2018
Manali Phadke Lily L. Remsing Rix Inna Smalley Annamarie T. Bryant Yunting Luo Harshani R. Lawrence Braydon J. Schaible Yian A. Chen Uwe Rix Keiran S. M. Smalley

Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF-mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth of NRAS-mutant and KRAS-mutant cancer cell lines than vemurafenib. Using mass spectrometry-based chemical proteomics, we identified NEK9 and CDK16 as ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Douglas B Johnson Keiran S M Smalley Jeffrey A Sosman

Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be an elusive target. Activating mutations in RAS induce mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase-AK...

2012
Ruchi Singhal Eugene S. Kandel

While new drugs aimed at BRAF-mutated cancers are entering clinical practice, cells and tumors with activating Ras mutations are relatively resistant to those and quite a few other anti-cancer agents. This inspires the effort to reverse this resistance or to uncover new vulnerabilities in such resistant cancers. IPA3 has been originally identified as a small molecule inhibitor of p21-activated ...

2018
Xiangyan Zhang Wenwen Ran Jie Wu Hong Li Huamin Liu Lili Wang Yujing Xiao Xiaonan Wang Yujun Li Xiaoming Xing

Objectives To investigate the frequency and prognostic role of deficient mismatch repair (dMMR) and RAS mutation in Chinese patients with colorectal carcinoma. Methods Clinical and pathological information from 813 patients were reviewed and recorded. Expression of mismatch repair proteins was tested by immunohistochemistry. Mutation analyses for RAS gene were performed by real-time polymeras...

2016
Danilo Fiore Elvira Donnarumma Giuseppina Roscigno Margherita Iaboni Valentina Russo Alessandra Affinito Assunta Adamo Fabio De Martino Cristina Quintavalle Giulia Romano Adelaide Greco Ylermi Soini Arturo Brunetti Carlo M. Croce Gerolama Condorelli

Glioblastoma is the most common primary brain tumor in adults; with a survival rate of 12 months from diagnosis. However, a small subgroup of patients, termed long-term survivors (LTS), has a survival rate longer then 12-14 months. There is thus increasing interest in the identification of molecular signatures predicting glioblastoma prognosis and in how to improve the therapeutic approach. Her...

Journal: :Cancer research 2015
Catherine A Eberlein Daniel Stetson Aleksandra A Markovets Katherine J Al-Kadhimi Zhongwu Lai Paul R Fisher Catherine B Meador Paula Spitzler Eiki Ichihara Sarah J Ross Miika J Ahdesmaki Ambar Ahmed Laura E Ratcliffe Elizabeth L Christey O'Brien Claire H Barnes Henry Brown Paul D Smith Jonathan R Dry Garry Beran Kenneth S Thress Brian Dougherty William Pao Darren A E Cross

Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and ...

2015
Yeong Hwan Ko Goli Nagaraju Jae Su Yu

Vertically aligned ZnO nanorod array (NRA)-based ultraviolet (UV) photodetectors (PDs) were successfully fabricated and optimized via a facile hydrothermal process. Using a shadow mask technique, the thin ZnO seed layer was deposited between the patterned Au/Ti electrodes to bridge the electrodes. Thus, both the Au electrodes could be connected by the ZnO seed layer. As the sample was immersed ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید